Compass Therapeutics Inc.
compasstherapeutics.comWhat Do They Do?
Develops antibody-based cancer therapies for patients with solid tumors and other cancers.
10-K for FY2025, filed Mar 5, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$25.2MView ↗
- ▲ +27% (Loss)
- vs −$19.9M in Q2 FY2025
-
Apr 27, 2026
Reports trial results: progression-free survival improved, overall-survival endpoint missed
Median progression-free survival was 4.7 months versus 2.6 months; the study did not meet its overall-survival endpoint.
Sources
8-K, filed Apr 27, 2026
Progression-Free Survival (PFS): Tovecimig in combination with paclitaxel demonstrated a statistically significant improvement in median…View ↗
Added pipeline candidate
The latest report adds a bispecific antibody candidate to the pipeline; the older report's pipeline list did not include it.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 5, 2026Our pipeline is comprised of three product candidates. Our lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like…View ↗
Our pipeline consists of four clinical product candidates. Our lead product candidate, tovecimig (formerly known as CTX-009), is a…View ↗
Who Do They Compete With?
Competes with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck &, Merck KGaA, Novartis, Pfizer, Roche Holding, and Sanofi
10-K for FY2025, filed Mar 5, 2026The biotechnology and pharmaceutical industries, and the immuno-oncology subsector, are characterized by rapid evolution of technologies…View ↗
Loading...
